Proton therapy
Proton therapy, also called proton beam therapy, is a form of radiation therapy that uses accelerated protons to deliver ionizing radiation to a defined clinical target volume.
Proton therapy, also called proton beam therapy, is a form of radiation therapy that uses accelerated protons to deliver ionizing radiation to a defined clinical target volume. Its dose distribution is characterized by the Bragg peak, allowing treatment planning to concentrate radiation near a selected depth while potentially limiting exposure beyond the target. Treatment planning may therefore consider the gross tumor volume, planning target volume, and nearby organs at risk, often using computed tomography, dose-volume histograms, and comparisons with photon therapy.
The biological effect of proton therapy results from radiation-induced damage to tumor cells and other irradiated tissues. Its clinical investigation spans pediatric and adult tumors, central nervous system disease, head and neck cancer, liver tumors, and biliary tract malignancies. Current work includes treatment selection, robust and adaptive planning, compact treatment systems, long-term quality of life, late effects, and imaging of proton-induced activity.
Rebuilt from PubMed 11 Sept 2026 · no new papers today
Where the papers sit
9 papers study proton therapy directly. Those 9 are one subject: Proton Radiotherapy Applications. Clinical proton radiotherapy work spans adaptive and robust planning, patient selection, and proton-induced PET/CT imaging. Outcomes include arterial enhancement after hepatocellular carcinoma treatment, long-term quality of life, and late effects across pediatric and adult tumors, without a single dominant direction. No way of splitting those 9 scores better than chance.
Recent Findings on proton therapy
A single-institution survey in Japan examined disease-specific late effects among pediatric solid-tumor and central nervous system tumor survivors who had received proton beam therapy. The mailed questionnaire was conducted between 2015 and 2021 and included 304 survivors treated at the University of Tsukuba Hospital between 1984 and 2020. The study focused on the burden of late effects after treatment, including outcomes relevant to long-term survivorship and potential neurocognitive impairment 42153532May.
A study of total-body dynamic positron-emission tomography/computed tomography investigated proton-induced activity and its biologic washout after proton therapy. It addressed limitations of conventional offline PET imaging, including transport delay after treatment, scanner sensitivity, and the short axial field of view, which restrict imaging of ultralow activity and whole-body washout. The work therefore connected proton therapy with PET/CT-based assessment of treatment-related activity and its time-dependent distribution 42276783Jun.
In untreated solitary hepatocellular carcinoma, investigators evaluated the prognostic significance of persistent arterial-phase hyperenhancement on contrast-enhanced computed tomography or magnetic resonance imaging at 6 and 12 months after proton beam therapy. The study specifically examined whether post-treatment APHE could provide clinically relevant information during imaging follow-up of liver tumors treated with proton therapy 42675808Sep.
A prospective study assessed five-year changes in health-related quality of life after proton therapy in a cohort consisting primarily of patients with meningioma and other benign intracranial or sellar-region tumors. It addressed the limited availability of long-term patient-reported outcome data in this population and evaluated quality of life over an extended follow-up period 42629514Aug.
A model-based selection study in oral cancer examined which patients might benefit more from passive-scattering proton beam therapy than from photon therapy. The stated purpose was to identify patients for whom proton treatment could reduce late adverse events. The approach represents a patient-selection strategy that uses treatment-planning considerations rather than applying proton therapy uniformly across all oral cancer cases 42241327Jun.
Investigators evaluated robust treatment planning for central nervous system tumors on a compact, gantry-less proton therapy system. The work assessed clinical feasibility with the aim of supporting more affordable and accessible proton systems. Robust planning is particularly relevant to maintaining target coverage and protecting organs at risk when treatment geometry or proton range is uncertain 42309151Jun.
A multicenter prospective registry study examined proton beam therapy for patients with unresectable distal cholangiocarcinoma, with particular attention to the influence of age and outcomes in elderly patients. The study focused on the role of proton therapy in this biliary tract cancer setting and evaluated whether age was an important factor in treatment assessment 42003161Apr.
Another clinical study evaluated the efficacy and toxicity of proton beam therapy for cancers of the external auditory canal and middle ear. These tumors are located in anatomically complex head and neck regions, where treatment planning must account for nearby normal tissues and organs at risk. The publication specifically investigated treatment effectiveness and adverse effects in this disease group 42018693Apr.
A digital-twin framework was developed for fast online adaptive proton therapy planning in prostate stereotactic body radiation therapy, including a dominant intraprostatic lesion boost. The framework sought to produce clinically equivalent plan quality while substantially reducing reoptimization time compared with traditional clinical workflows. This work combined proton therapy with adaptive planning, image-guided computational modeling, and automated plan generation; related technical approaches in this area include deep learning and segmentation or image-comparison metrics such as the Dice similarity coefficient, normalized cross-correlation, and mean absolute error 42361838Jun.
Collectively, these publications extend the broader theme of proton radiotherapy applications rather than defining separate therapeutic categories. The recent work covers survivorship and fatigue-related quality-of-life assessment, tumor-specific outcome evaluation, selection against photon therapy, robust planning for the clinical target volume, and emerging imaging and adaptive-planning technologies. It also illustrates the continuing emphasis on balancing local control and target coverage against late toxicity, neurocognitive impairment, and other effects on normal tissue.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-09-11. Drafted by language models from published abstracts; not medical advice.